Great question Led. There haven't been any changes to the BETonMACE ClinicalTrials.gov listing for over a year now. Since they seem to be running on fumes in terms of funding right now, I don't see how they can afford to activate US study sites and dose US patients in BETonMACE until they raise more $. Same goes for the Renal trial. Same goes for the Fabry trial. No $, no start of Renal/Fabry trials or expansion of BETonMACE in the US. Am I missing something? Does someone who follows the companies financials more closely want to counter my view here and re-assure us that they have funds on hand for the Renal, Fabry, US BETonMACE? If not, then we likely need to wait for the futility analysis to hopefully trigger this latest rumored deal.

Keep in mind the forward looking statement part of the news release (copied below). Sound like some on this board are very re-assured that all is well based on the news release. I feel no better than I did prior to the news release. Nothing has changed other than extending the loan maturity date......which is great but not a problem solver in itself.

"This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to an extension of the maturity date of the Company's loan, the expectation that the Company will close a strategic transaction involving a licensing arrangement prior to the amended maturity date of the Loan, and the potential role of apabetalone in the treatment of CVD, DM, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. In particular, there is no assurance that the Company will complete a strategic transaction or that the proceeds from any such transaction will be sufficient to enable the Company to repay the Loan by the amended maturity date."